NICE recommends funding for three thyroid cancer drugs

NICE has recommended in draft guidance that three thyroid cancer treatments can receive regular NHS funding, finally approving a drug from Eisai after a delay of more than two years because it fell through several gaps in the body’s review process.
All the drugs got through NICE after the manufacturers offered commercially confidential discounts.
Eisai’s Lenvima (lenvatinib) was refused entry into the Cancer Drugs Fund (CDF) in 2016, because the scheme to provide interim funding for oncology drugs that cannot be funded regularly on the NHS was closed to new entries at the time.
Lenvima was also not scheduled for assessment by NICE because of its low budget impact, and as a result NICE delayed its review of the drug’s cost-effectiveness.
Gary Hendler, chairman & CEO EMEA, and chief commercial officer, Oncology Business Group at Eisai, said: “After almost three years of being licensed in the EU, I am really very pleased that NICE is finally recommending the use of lenvatinib so that patients with this form of thyroid cancer will at last have access to it in England. While patients in Scotland and Wales had access to lenvatinib much sooner – 2016 and 2017 respectively – it’s a real shame that due to a poor process that patients in England have had to wait much longer.”
NICE has said that two other drugs previously funded by the CDF under previous arrangements can now receive regular funding on the NHS.
It said that Ipsen’s Cometriq (cabozantinib), and Bayer’s Nexavar (lenvatinib) can be made available through usual arrangements after being reimbursed by the CDF.
Around 1,300 people could benefit from these treatment over the next five years, NICE said.
NICE made the decision in two separate appraisals – in one it said Cometriq (cabozantinib) is recommended as an option for treating medullary thyroid cancer that cannot be operated on or has spread around the body. This is a rare type of thyroid cancer, affecting only 80 people in England each year.
In a separate appraisal NICE said Lenvima and Nexavar are recommended for cancers that have continued to grow or spread around after surgery and radioactive iodine therapy – a kind of cancer affecting around 200 people each year.
Mirella Marlow, acting director of the NICE centre for health technology evaluation, said: “Treatment options for these types of thyroid cancer are limited, so it is important that we are able to give patients much needed access to alternatives to best supportive care at this stage of their disease. These drugs will give patients extra time, as well as improving their quality of life.”
In Scotland, all the drugs have already been funded by the NHS under devolved decision making by the Scottish Medicines Consortium.
Source:https://pharmaphorum.com/news/nice-recommends-funding-three-thyroid-cancer-drugs/

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more